A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-ov65)

Hoki Toshifumi0 个研究点目标入组 40 人开始时间: 2022年3月2日最近更新: 2023年10月17日

适应症

试验速览

阶段: 3 期
状态: 进行中（未招募）
发起方
入组人数: 40

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 ot applicable（—）
性别: Female

入选标准

•Has histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
•- Has received 1 or 2 prior lines of systemic therapy for ovarian cancer (OC), including at least 1 prior platinum-based therapy. Participants may have received a prior poly (ADP-ribose) polymerase inhibitor (PARPi), anti-PD-1/anti-PD-L1 therapy or bevacizumab; these will not be considered a separate line of therapy. Any chemotherapy regimen change due to toxicity in the absence of disease progression will be considered part of the same line of therapy.
•- Has provided documented informed consent for the study.
•- Has radiographic evidence of disease progression within 6 months (180 days) after the last dose of platinum-based chemotherapy for OC (i.e., platinum-resistant disease).
•- Is a candidate for paclitaxel chemotherapy (and bevacizumab, if using).
•- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 3 days before randomization.
•- For a female participant, she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP and uses a contraceptive method that is highly effective (with a failure rate of <1% per year).
•- Has radiographically evaluable disease, either measurable or nonmeasurable per RECIST 1.1, as assessed by the local site investigator.
•- Archival tumor tissue sample or newly obtained core or incisional/excisional biopsy of a tumor lesion not previously irradiated has been provided.
•- Have adequate organ function.

排除标准

•- Has nonepithelial cancers, borderline tumors, mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor and undifferentiated carcinoma.
•- Has primary platinum-refractory disease, defined as disease that has progressed per RECIST 1.1 while receiving first-line platinum-based therapy.
•- Has prior disease progression on weekly paclitaxel alone.
•- Has uncontrolled hypertension.
•- Has current, clinically relevant bowel obstruction including related to underlying epithelial OC, abdominal fistula or gastrointestinal perforation, intra-abdominal abscess, or evidence of rectosigmoid involvement by pelvic exam.
•- Has a history of thrombotic disorders, hemorrhage, hemoptysis, or active gastrointestinal bleeding within 6 months before randomization.
•- Has received >2 prior lines of systemic therapy for OC.
•- Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.
•- Has received prior radiation therapy within 2 weeks of start of study intervention.
•- Has not recovered adequately from surgery and/or any complications from the surgery.
•- Has received colony-stimulating factors (e.g., granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor,[GM-CSF] or recombinant erythropoietin) within 4 weeks before randomization.
•- Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
•- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.
•- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.
•- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
•- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
•- Has severe hypersensitivity (>=Grade 3) to pembrolizumab, paclitaxel, or bevacizumab (if using) and/or any of their excipients.
•- Has an active autoimmune disease that has required systemic treatment in the past 2 years.
•- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
•- Has an active infection requiring systemic therapy.
•- Has a known history of human immunodeficiency virus (HIV) infection.
•- Has a known history of Hepatitis B or known active Hepatitis C virus infection.
•- Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study.
•- Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
•- Participant, in the judgement of the investigator, is unlikely to comply with the study procedures, restrictions, and requirements of the study.
•- Has had an allogenic tissue/solid organ transplant.

研究者

发起方

Hoki Toshifumi

相似试验

进行中（未招募）

1 期

Phase 3 1L Study of Pembrolizumab ± Ipilimumab in NSCLCMetastatic programmed cell deathligand 1 (PD-L1) positive (TPS =50%) non-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-004364-20-HUMerck Sharp & Dohme Corp.,a subsidiary of Merck & Co.,Inc.568

进行中（未招募）

1 期

A study with chemotherapy plus pembrolizumab or placebo after curative surgery for endometrial cancer in women 18 years or olderMedDRA version: 21.0Level: PTClassification code 10014733Term: Endometrial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-003424-17-NOMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990

进行中（未招募）

1 期

Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer.Platinum-resistant Recurrent Ovarian CancerMedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-005027-37-NOMerck Sharp & Dohme LLC616

进行中（未招募）

1 期

EUCTR2020-003424-17-PLMerck Sharp & Dohme LLC990

进行中（未招募）

1 期

EUCTR2016-004364-20-LVMerck Sharp & Dohme Corp.,a subsidiary of Merck & Co.,Inc.568